TLR2 and ulcerative colitis: Another study [39] showed that TRIM58 might protect against the transduction of intestinal mucosal inflammation by inhibiting abnormal TLR2 signaling and serve as a potential therapeutic target in autoimmune diseases, such as ulcerative colitis.